Global Monoclonal Antibody VEGF Inhibitors Market Outlook, In‑Depth Analysis & Forecast to 2031

1 Study Coverage
1.1 Introduction to Monoclonal Antibody VEGF Inhibitors: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Monoclonal Antibody VEGF Inhibitors Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Ramucirumab
1.2.3 Bevacizumab
1.2.4 Ranibizumab
1.2.5 Brolucizumab
1.2.6 Faricimab
1.2.7 Other
1.3 Market Segmentation by Application
1.3.1 Global Monoclonal Antibody VEGF Inhibitors Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Degenerative Eye Diseases
1.3.3 Cancer
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Monoclonal Antibody VEGF Inhibitors Revenue Estimates and Forecasts 2020-2031
2.2 Global Monoclonal Antibody VEGF Inhibitors Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Monoclonal Antibody VEGF Inhibitors Sales Estimates and Forecasts 2020-2031
2.4 Global Monoclonal Antibody VEGF Inhibitors Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Monoclonal Antibody VEGF Inhibitors Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Monoclonal Antibody VEGF Inhibitors Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Ramucirumab Market Size by Manufacturers
3.5.2 Bevacizumab Market Size by Manufacturers
3.5.3 Ranibizumab Market Size by Manufacturers
3.5.4 Brolucizumab Market Size by Manufacturers
3.5.5 Faricimab Market Size by Manufacturers
3.5.6 Other Market Size by Manufacturers
3.6 Global Monoclonal Antibody VEGF Inhibitors Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Monoclonal Antibody VEGF Inhibitors Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Monoclonal Antibody VEGF Inhibitors Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Monoclonal Antibody VEGF Inhibitors Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Monoclonal Antibody VEGF Inhibitors Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Monoclonal Antibody VEGF Inhibitors Sales and Revenue by Type (2020-2031)
6.4 North America Monoclonal Antibody VEGF Inhibitors Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Monoclonal Antibody VEGF Inhibitors Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Monoclonal Antibody VEGF Inhibitors Sales and Revenue by Type (2020-2031)
7.4 Europe Monoclonal Antibody VEGF Inhibitors Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Monoclonal Antibody VEGF Inhibitors Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Monoclonal Antibody VEGF Inhibitors Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Monoclonal Antibody VEGF Inhibitors Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Monoclonal Antibody VEGF Inhibitors Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Monoclonal Antibody VEGF Inhibitors Sales and Revenue by Type (2020-2031)
9.4 Central and South America Monoclonal Antibody VEGF Inhibitors Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Monoclonal Antibody VEGF Inhibitors Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Monoclonal Antibody VEGF Inhibitors Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Monoclonal Antibody VEGF Inhibitors Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Monoclonal Antibody VEGF Inhibitors Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Roche
11.1.1 Roche Corporation Information
11.1.2 Roche Business Overview
11.1.3 Roche Monoclonal Antibody VEGF Inhibitors Product Models, Descriptions and Specifications
11.1.4 Roche Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Roche Monoclonal Antibody VEGF Inhibitors Sales by Product in 2024
11.1.6 Roche Monoclonal Antibody VEGF Inhibitors Sales by Application in 2024
11.1.7 Roche Monoclonal Antibody VEGF Inhibitors Sales by Geographic Area in 2024
11.1.8 Roche Monoclonal Antibody VEGF Inhibitors SWOT Analysis
11.1.9 Roche Recent Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Corporation Information
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Monoclonal Antibody VEGF Inhibitors Product Models, Descriptions and Specifications
11.2.4 Eli Lilly Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Eli Lilly Monoclonal Antibody VEGF Inhibitors Sales by Product in 2024
11.2.6 Eli Lilly Monoclonal Antibody VEGF Inhibitors Sales by Application in 2024
11.2.7 Eli Lilly Monoclonal Antibody VEGF Inhibitors Sales by Geographic Area in 2024
11.2.8 Eli Lilly Monoclonal Antibody VEGF Inhibitors SWOT Analysis
11.2.9 Eli Lilly Recent Developments
11.3 Pfizer
11.3.1 Pfizer Corporation Information
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Monoclonal Antibody VEGF Inhibitors Product Models, Descriptions and Specifications
11.3.4 Pfizer Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Pfizer Monoclonal Antibody VEGF Inhibitors Sales by Product in 2024
11.3.6 Pfizer Monoclonal Antibody VEGF Inhibitors Sales by Application in 2024
11.3.7 Pfizer Monoclonal Antibody VEGF Inhibitors Sales by Geographic Area in 2024
11.3.8 Pfizer Monoclonal Antibody VEGF Inhibitors SWOT Analysis
11.3.9 Pfizer Recent Developments
11.4 Celltrion Healthcare
11.4.1 Celltrion Healthcare Corporation Information
11.4.2 Celltrion Healthcare Business Overview
11.4.3 Celltrion Healthcare Monoclonal Antibody VEGF Inhibitors Product Models, Descriptions and Specifications
11.4.4 Celltrion Healthcare Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Celltrion Healthcare Monoclonal Antibody VEGF Inhibitors Sales by Product in 2024
11.4.6 Celltrion Healthcare Monoclonal Antibody VEGF Inhibitors Sales by Application in 2024
11.4.7 Celltrion Healthcare Monoclonal Antibody VEGF Inhibitors Sales by Geographic Area in 2024
11.4.8 Celltrion Healthcare Monoclonal Antibody VEGF Inhibitors SWOT Analysis
11.4.9 Celltrion Healthcare Recent Developments
11.5 Amgen
11.5.1 Amgen Corporation Information
11.5.2 Amgen Business Overview
11.5.3 Amgen Monoclonal Antibody VEGF Inhibitors Product Models, Descriptions and Specifications
11.5.4 Amgen Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Amgen Monoclonal Antibody VEGF Inhibitors Sales by Product in 2024
11.5.6 Amgen Monoclonal Antibody VEGF Inhibitors Sales by Application in 2024
11.5.7 Amgen Monoclonal Antibody VEGF Inhibitors Sales by Geographic Area in 2024
11.5.8 Amgen Monoclonal Antibody VEGF Inhibitors SWOT Analysis
11.5.9 Amgen Recent Developments
11.6 Amneal Pharmaceuticals,
11.6.1 Amneal Pharmaceuticals, Corporation Information
11.6.2 Amneal Pharmaceuticals, Business Overview
11.6.3 Amneal Pharmaceuticals, Monoclonal Antibody VEGF Inhibitors Product Models, Descriptions and Specifications
11.6.4 Amneal Pharmaceuticals, Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Amneal Pharmaceuticals, Recent Developments
11.7 Coherus BioSciences
11.7.1 Coherus BioSciences Corporation Information
11.7.2 Coherus BioSciences Business Overview
11.7.3 Coherus BioSciences Monoclonal Antibody VEGF Inhibitors Product Models, Descriptions and Specifications
11.7.4 Coherus BioSciences Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Coherus BioSciences Recent Developments
11.8 Novartis
11.8.1 Novartis Corporation Information
11.8.2 Novartis Business Overview
11.8.3 Novartis Monoclonal Antibody VEGF Inhibitors Product Models, Descriptions and Specifications
11.8.4 Novartis Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Novartis Recent Developments
11.9 Chia Tai Tianqing
11.9.1 Chia Tai Tianqing Corporation Information
11.9.2 Chia Tai Tianqing Business Overview
11.9.3 Chia Tai Tianqing Monoclonal Antibody VEGF Inhibitors Product Models, Descriptions and Specifications
11.9.4 Chia Tai Tianqing Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Chia Tai Tianqing Recent Developments
11.10 Qilu Pharma
11.10.1 Qilu Pharma Corporation Information
11.10.2 Qilu Pharma Business Overview
11.10.3 Qilu Pharma Monoclonal Antibody VEGF Inhibitors Product Models, Descriptions and Specifications
11.10.4 Qilu Pharma Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Qilu Pharma Recent Developments
11.11 Boan Biotech
11.11.1 Boan Biotech Corporation Information
11.11.2 Boan Biotech Business Overview
11.11.3 Boan Biotech Monoclonal Antibody VEGF Inhibitors Product Models, Descriptions and Specifications
11.11.4 Boan Biotech Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Boan Biotech Recent Developments
11.12 Jiangsu Hengrui Pharmaceuticals
11.12.1 Jiangsu Hengrui Pharmaceuticals Corporation Information
11.12.2 Jiangsu Hengrui Pharmaceuticals Business Overview
11.12.3 Jiangsu Hengrui Pharmaceuticals Monoclonal Antibody VEGF Inhibitors Product Models, Descriptions and Specifications
11.12.4 Jiangsu Hengrui Pharmaceuticals Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
11.13 SinoCellTech
11.13.1 SinoCellTech Corporation Information
11.13.2 SinoCellTech Business Overview
11.13.3 SinoCellTech Monoclonal Antibody VEGF Inhibitors Product Models, Descriptions and Specifications
11.13.4 SinoCellTech Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 SinoCellTech Recent Developments
11.14 Innovent
11.14.1 Innovent Corporation Information
11.14.2 Innovent Business Overview
11.14.3 Innovent Monoclonal Antibody VEGF Inhibitors Product Models, Descriptions and Specifications
11.14.4 Innovent Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.14.5 Innovent Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Monoclonal Antibody VEGF Inhibitors Industry Chain
12.2 Monoclonal Antibody VEGF Inhibitors Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Monoclonal Antibody VEGF Inhibitors Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Monoclonal Antibody VEGF Inhibitors Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Monoclonal Antibody VEGF Inhibitors Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Monoclonal Antibody VEGF Inhibitors Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

List of Tables
Table 1. Global Monoclonal Antibody VEGF Inhibitors Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Monoclonal Antibody VEGF Inhibitors Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Monoclonal Antibody VEGF Inhibitors Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Monoclonal Antibody VEGF Inhibitors Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Monoclonal Antibody VEGF Inhibitors Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Monoclonal Antibody VEGF Inhibitors Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Monoclonal Antibody VEGF Inhibitors Sales by Region (2020-2025) & (K Units)
Table 8. Global Monoclonal Antibody VEGF Inhibitors Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Monoclonal Antibody VEGF Inhibitors Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Monoclonal Antibody VEGF Inhibitors Sales Share by Manufacturers (2020-2025)
Table 12. Global Monoclonal Antibody VEGF Inhibitors Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Monoclonal Antibody VEGF Inhibitors by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal Antibody VEGF Inhibitors as of 2024)
Table 16. Global Monoclonal Antibody VEGF Inhibitors Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Monoclonal Antibody VEGF Inhibitors Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Monoclonal Antibody VEGF Inhibitors Manufacturing Base and Headquarters
Table 19. Global Monoclonal Antibody VEGF Inhibitors Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Monoclonal Antibody VEGF Inhibitors Sales by Type (2020-2025) & (K Units)
Table 23. Global Monoclonal Antibody VEGF Inhibitors Sales by Type (2026-2031) & (K Units)
Table 24. Global Monoclonal Antibody VEGF Inhibitors Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Monoclonal Antibody VEGF Inhibitors Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Monoclonal Antibody VEGF Inhibitors ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Monoclonal Antibody VEGF Inhibitors Sales by Application (2020-2025) & (K Units)
Table 29. Global Monoclonal Antibody VEGF Inhibitors Sales by Application (2026-2031) & (K Units)
Table 30. Monoclonal Antibody VEGF Inhibitors High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Monoclonal Antibody VEGF Inhibitors Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Monoclonal Antibody VEGF Inhibitors Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Monoclonal Antibody VEGF Inhibitors ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Monoclonal Antibody VEGF Inhibitors Growth Accelerators and Market Barriers
Table 37. North America Monoclonal Antibody VEGF Inhibitors Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Monoclonal Antibody VEGF Inhibitors Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Monoclonal Antibody VEGF Inhibitors Growth Accelerators and Market Barriers
Table 40. Europe Monoclonal Antibody VEGF Inhibitors Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Monoclonal Antibody VEGF Inhibitors Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Monoclonal Antibody VEGF Inhibitors Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Monoclonal Antibody VEGF Inhibitors Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Monoclonal Antibody VEGF Inhibitors Growth Accelerators and Market Barriers
Table 45. Southeast Asia Monoclonal Antibody VEGF Inhibitors Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Monoclonal Antibody VEGF Inhibitors Investment Opportunities and Key Challenges
Table 47. Central and South America Monoclonal Antibody VEGF Inhibitors Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Monoclonal Antibody VEGF Inhibitors Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Monoclonal Antibody VEGF Inhibitors Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Roche Corporation Information
Table 51. Roche Description and Major Businesses
Table 52. Roche Product Models, Descriptions and Specifications
Table 53. Roche Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Roche Sales Value Proportion by Product in 2024
Table 55. Roche Sales Value Proportion by Application in 2024
Table 56. Roche Sales Value Proportion by Geographic Area in 2024
Table 57. Roche Monoclonal Antibody VEGF Inhibitors SWOT Analysis
Table 58. Roche Recent Developments
Table 59. Eli Lilly Corporation Information
Table 60. Eli Lilly Description and Major Businesses
Table 61. Eli Lilly Product Models, Descriptions and Specifications
Table 62. Eli Lilly Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Eli Lilly Sales Value Proportion by Product in 2024
Table 64. Eli Lilly Sales Value Proportion by Application in 2024
Table 65. Eli Lilly Sales Value Proportion by Geographic Area in 2024
Table 66. Eli Lilly Monoclonal Antibody VEGF Inhibitors SWOT Analysis
Table 67. Eli Lilly Recent Developments
Table 68. Pfizer Corporation Information
Table 69. Pfizer Description and Major Businesses
Table 70. Pfizer Product Models, Descriptions and Specifications
Table 71. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Pfizer Sales Value Proportion by Product in 2024
Table 73. Pfizer Sales Value Proportion by Application in 2024
Table 74. Pfizer Sales Value Proportion by Geographic Area in 2024
Table 75. Pfizer Monoclonal Antibody VEGF Inhibitors SWOT Analysis
Table 76. Pfizer Recent Developments
Table 77. Celltrion Healthcare Corporation Information
Table 78. Celltrion Healthcare Description and Major Businesses
Table 79. Celltrion Healthcare Product Models, Descriptions and Specifications
Table 80. Celltrion Healthcare Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Celltrion Healthcare Sales Value Proportion by Product in 2024
Table 82. Celltrion Healthcare Sales Value Proportion by Application in 2024
Table 83. Celltrion Healthcare Sales Value Proportion by Geographic Area in 2024
Table 84. Celltrion Healthcare Monoclonal Antibody VEGF Inhibitors SWOT Analysis
Table 85. Celltrion Healthcare Recent Developments
Table 86. Amgen Corporation Information
Table 87. Amgen Description and Major Businesses
Table 88. Amgen Product Models, Descriptions and Specifications
Table 89. Amgen Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Amgen Sales Value Proportion by Product in 2024
Table 91. Amgen Sales Value Proportion by Application in 2024
Table 92. Amgen Sales Value Proportion by Geographic Area in 2024
Table 93. Amgen Monoclonal Antibody VEGF Inhibitors SWOT Analysis
Table 94. Amgen Recent Developments
Table 95. Amneal Pharmaceuticals, Corporation Information
Table 96. Amneal Pharmaceuticals, Description and Major Businesses
Table 97. Amneal Pharmaceuticals, Product Models, Descriptions and Specifications
Table 98. Amneal Pharmaceuticals, Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Amneal Pharmaceuticals, Recent Developments
Table 100. Coherus BioSciences Corporation Information
Table 101. Coherus BioSciences Description and Major Businesses
Table 102. Coherus BioSciences Product Models, Descriptions and Specifications
Table 103. Coherus BioSciences Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Coherus BioSciences Recent Developments
Table 105. Novartis Corporation Information
Table 106. Novartis Description and Major Businesses
Table 107. Novartis Product Models, Descriptions and Specifications
Table 108. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Novartis Recent Developments
Table 110. Chia Tai Tianqing Corporation Information
Table 111. Chia Tai Tianqing Description and Major Businesses
Table 112. Chia Tai Tianqing Product Models, Descriptions and Specifications
Table 113. Chia Tai Tianqing Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Chia Tai Tianqing Recent Developments
Table 115. Qilu Pharma Corporation Information
Table 116. Qilu Pharma Description and Major Businesses
Table 117. Qilu Pharma Product Models, Descriptions and Specifications
Table 118. Qilu Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Qilu Pharma Recent Developments
Table 120. Boan Biotech Corporation Information
Table 121. Boan Biotech Description and Major Businesses
Table 122. Boan Biotech Product Models, Descriptions and Specifications
Table 123. Boan Biotech Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Boan Biotech Recent Developments
Table 125. Jiangsu Hengrui Pharmaceuticals Corporation Information
Table 126. Jiangsu Hengrui Pharmaceuticals Description and Major Businesses
Table 127. Jiangsu Hengrui Pharmaceuticals Product Models, Descriptions and Specifications
Table 128. Jiangsu Hengrui Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. Jiangsu Hengrui Pharmaceuticals Recent Developments
Table 130. SinoCellTech Corporation Information
Table 131. SinoCellTech Description and Major Businesses
Table 132. SinoCellTech Product Models, Descriptions and Specifications
Table 133. SinoCellTech Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 134. SinoCellTech Recent Developments
Table 135. Innovent Corporation Information
Table 136. Innovent Description and Major Businesses
Table 137. Innovent Product Models, Descriptions and Specifications
Table 138. Innovent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 139. Innovent Recent Developments
Table 140. Key Raw Materials Distribution
Table 141. Raw Materials Key Suppliers
Table 142. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 143. Milestones in Production Technology Evolution
Table 144. Distributors List
Table 145. Market Trends and Market Evolution
Table 146. Market Drivers and Opportunities
Table 147. Market Challenges, Risks, and Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources


List of Figures
Figure 1. Monoclonal Antibody VEGF Inhibitors Product Picture
Figure 2. Global Monoclonal Antibody VEGF Inhibitors Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Ramucirumab Product Picture
Figure 4. Bevacizumab Product Picture
Figure 5. Ranibizumab Product Picture
Figure 6. Brolucizumab Product Picture
Figure 7. Faricimab Product Picture
Figure 8. Other Product Picture
Figure 9. Global Monoclonal Antibody VEGF Inhibitors Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 10. Degenerative Eye Diseases
Figure 11. Cancer
Figure 12. Other
Figure 13. Monoclonal Antibody VEGF Inhibitors Report Years Considered
Figure 14. Global Monoclonal Antibody VEGF Inhibitors Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Monoclonal Antibody VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 16. Global Monoclonal Antibody VEGF Inhibitors Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 17. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Region (2020-2031)
Figure 18. Global Monoclonal Antibody VEGF Inhibitors Sales (2020-2031) & (K Units)
Figure 19. Global Monoclonal Antibody VEGF Inhibitors Sales (CAGR) by Region (2020-2031) (K Units)
Figure 20. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Region (2020-2031)
Figure 21. Top 5 and Top 10 Manufacturers Monoclonal Antibody VEGF Inhibitors Sales Volume Market Share in 2024
Figure 22. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share Ranking (2024)
Figure 23. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 24. Ramucirumab Revenue Market Share by Manufacturer in 2024
Figure 25. Bevacizumab Revenue Market Share by Manufacturer in 2024
Figure 26. Ranibizumab Revenue Market Share by Manufacturer in 2024
Figure 27. Brolucizumab Revenue Market Share by Manufacturer in 2024
Figure 28. Faricimab Revenue Market Share by Manufacturer in 2024
Figure 29. Other Revenue Market Share by Manufacturer in 2024
Figure 30. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Type (2020-2031)
Figure 31. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Type (2020-2031)
Figure 32. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Application (2020-2031)
Figure 33. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Application (2020-2031)
Figure 34. North America Monoclonal Antibody VEGF Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 35. North America Monoclonal Antibody VEGF Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 36. North America Top 5 Manufacturers Monoclonal Antibody VEGF Inhibitors Sales Revenue (US$ Million) in 2024
Figure 37. North America Monoclonal Antibody VEGF Inhibitors Sales Volume (K Units) by Type (2020- 2031)
Figure 38. North America Monoclonal Antibody VEGF Inhibitors Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 39. North America Monoclonal Antibody VEGF Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 40. North America Monoclonal Antibody VEGF Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 41. US Monoclonal Antibody VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 42. Canada Monoclonal Antibody VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 43. Mexico Monoclonal Antibody VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 44. Europe Monoclonal Antibody VEGF Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 45. Europe Monoclonal Antibody VEGF Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 46. Europe Top 5 Manufacturers Monoclonal Antibody VEGF Inhibitors Sales Revenue (US$ Million) in 2024
Figure 47. Europe Monoclonal Antibody VEGF Inhibitors Sales Volume (K Units) by Type (2020-2031)
Figure 48. Europe Monoclonal Antibody VEGF Inhibitors Sales Revenue (US$ Million) by Type (2020-2031)
Figure 49. Europe Monoclonal Antibody VEGF Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 50. Europe Monoclonal Antibody VEGF Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 51. Germany Monoclonal Antibody VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 52. France Monoclonal Antibody VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 53. U.K. Monoclonal Antibody VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 54. Italy Monoclonal Antibody VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 55. Russia Monoclonal Antibody VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 56. Asia-Pacific Monoclonal Antibody VEGF Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 57. Asia-Pacific Monoclonal Antibody VEGF Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Asia-Pacific Top 8 Manufacturers Monoclonal Antibody VEGF Inhibitors Sales Revenue (US$ Million) in 2024
Figure 59. Asia-Pacific Monoclonal Antibody VEGF Inhibitors Sales Volume (K Units) by Type (2020- 2031)
Figure 60. Asia-Pacific Monoclonal Antibody VEGF Inhibitors Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 61. Asia-Pacific Monoclonal Antibody VEGF Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 62. Asia-Pacific Monoclonal Antibody VEGF Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 63. Indonesia Monoclonal Antibody VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 64. Japan Monoclonal Antibody VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 65. South Korea Monoclonal Antibody VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 66. China Taiwan Monoclonal Antibody VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 67. India Monoclonal Antibody VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 68. Central and South America Monoclonal Antibody VEGF Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 69. Central and South America Monoclonal Antibody VEGF Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 70. Central and South America Top 5 Manufacturers Monoclonal Antibody VEGF Inhibitors Sales Revenue (US$ Million) in 2024
Figure 71. Central and South America Monoclonal Antibody VEGF Inhibitors Sales Volume (K Units) by Type (2021-2031)
Figure 72. Central and South America Monoclonal Antibody VEGF Inhibitors Sales Revenue (US$ Million) by Type (2020-2031)
Figure 73. Central and South America Monoclonal Antibody VEGF Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 74. Central and South America Monoclonal Antibody VEGF Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 75. Brazil Monoclonal Antibody VEGF Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 76. Argentina Monoclonal Antibody VEGF Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 77. Middle East, and Africa Monoclonal Antibody VEGF Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 78. Middle East and Africa Monoclonal Antibody VEGF Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 79. Middle East and Africa Top 5 Manufacturers Monoclonal Antibody VEGF Inhibitors Sales Revenue (US$ Million) in 2024
Figure 80. Middle East and Africa Monoclonal Antibody VEGF Inhibitors Sales Volume (K Units) by Type (2021-2031)
Figure 81. South America Monoclonal Antibody VEGF Inhibitors Sales Revenue (US$ Million) by Type (2020-2031)
Figure 82. Middle East and Africa Monoclonal Antibody VEGF Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 83. Middle East and Africa Monoclonal Antibody VEGF Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 84. GCC Countries Monoclonal Antibody VEGF Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 85. Turkey Monoclonal Antibody VEGF Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 86. Egypt Monoclonal Antibody VEGF Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 87. South Africa Monoclonal Antibody VEGF Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 88. Monoclonal Antibody VEGF Inhibitors Industry Chain Mapping
Figure 89. Regional Monoclonal Antibody VEGF Inhibitors Manufacturing Base Distribution (%)
Figure 90. Global Monoclonal Antibody VEGF Inhibitors Production Market Share by Region (2020-2031)
Figure 91. Monoclonal Antibody VEGF Inhibitors Production Process
Figure 92. Regional Monoclonal Antibody VEGF Inhibitors Production Cost Structure
Figure 93. Channels of Distribution (Direct Vs Distribution)
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit